Hsing-Chang Ni1,2,3, Yu-Ju Lin1,2,4, Susan Shur-Fen Gau1,2, Hui-Chun Huang5, Li-Kuang Yang1,2,6. 1. 1 National Taiwan University Hospital, Taipei, Taiwan. 2. 2 National Taiwan University College of Medicine, Taipei, Taiwan. 3. 3 Chang Gung Memorial Hospital at Linkou, Taiwan. 4. 4 Far Eastern Memorial Hospital, Taipei, Taiwan. 5. 5 National Cheng Kung University Hospital, Tainan, Taiwan. 6. 6 Beitou Armed Forces Hospital, Taipei, Taiwan.
Abstract
OBJECTIVE: To directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms, social functions, and quality of life among adults with ADHD. METHOD: This was an 8-to-10-week, open-label, head-to-head, randomized clinical trial with two treatment arms: immediate-release methylphenidate (IR-methylphenidate; n = 31) and atomoxetine once daily ( n = 32). The outcome measures included ADHD symptom severity, quality of life, and functional impairments. RESULTS: We found a significant reduction in overall ADHD symptoms and improvement in social functions and quality of life for both groups at Weeks 4 to 5 and Weeks 8 to 10. There was no significant difference in the slope of improvements over time except that atomoxetine was superior to IR-methylphenidate in reducing hyperactive/impulsive symptoms at Weeks 4 to 5. There was no significant group difference in the rates of adverse effects. CONCLUSION: Both IR-methylphenidate and atomoxetine are well tolerated and efficacious in ethnic Chinese adults with ADHD.
RCT Entities:
OBJECTIVE: To directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms, social functions, and quality of life among adults with ADHD. METHOD: This was an 8-to-10-week, open-label, head-to-head, randomized clinical trial with two treatment arms: immediate-release methylphenidate (IR-methylphenidate; n = 31) and atomoxetine once daily ( n = 32). The outcome measures included ADHD symptom severity, quality of life, and functional impairments. RESULTS: We found a significant reduction in overall ADHD symptoms and improvement in social functions and quality of life for both groups at Weeks 4 to 5 and Weeks 8 to 10. There was no significant difference in the slope of improvements over time except that atomoxetine was superior to IR-methylphenidate in reducing hyperactive/impulsive symptoms at Weeks 4 to 5. There was no significant group difference in the rates of adverse effects. CONCLUSION: Both IR-methylphenidate and atomoxetine are well tolerated and efficacious in ethnic Chinese adults with ADHD.
Entities:
Keywords:
adult ADHD; atomoxetine; life quality; methylphenidate; social function